MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Zura Bio Ltd (ZURA)

Zura Bio Ltd (ZURA)

|||

Cash Flow Overview

Change in Cash
-$116,091.273K
Free Cash flow
$18,896.139K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Net loss
    • Accounts payable and accrued exp...
    • Purchase of property and equipme...
    • Others
Negative Cash Flow Breakdown
    • Proceeds from issuance of class ...
    • Proceeds from issuance of pre-fu...
    • Share-based compensation expense
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
24,172.473
-24,223
-17,175
-18,040
Share-based compensation expense
-4,998.535
5,008
2,577
2,379
Deferred income taxes
-2.753
-
-
-
Depreciation and amortization
-15.968
16
15
14
Foreign exchange transaction loss
1.954
-2
-11
-6
Gain on extinguishment of baffx17 liability
-
-
5,000
-
Other non-cash items, net
-
-
-4
-
Loss on disposal of property and equipment
2.995
-3
-
-
Prepaid expenses and other current assets
1,494.343
-1,493
-372
780
Other assets
-1.511
-
0
814
Accounts payable and accrued expenses
1,225.74
-1,222
-3,082
1,791
Net cash used in operating activities
18,883.176
-18,923
-22,278
-15,444
Purchase of property and equipment
-12.963
13
17
32
Net cash used in investing activities
12.963
-13
-17
-32
Proceeds from issuance of class a ordinary shares in connection with february 2026 equity offering, net of 8.5 million of underwriters fees and discounts
-123,751.629
123,875
-
-
Proceeds from issuance of pre-funded warrants in connection with february 2026 equity offering, net of 0.7 million of underwriters fees and discounts
-11,236.798
11,248
-
-
Proceeds from exercise of pre-funded warrants
-
-
-
3
Proceeds from issuance of class a ordinary shares in connection with a sale under the atm, net of 0.2 million of commissions
0
0
0
0
Payment of employee withholding taxes for restricted stock units withheld
0
-
7
0
Issuance of class a ordinary shares upon exercise of pre-funded warrants
-
-
3
-
Consideration paid for athanor agreement
-
-
7,325
-
Proceeds from exercise of stock options
1.015
0
17
0
Net cash provided by financing activities
-134,987.412
135,123
-7,315
3
Net increase (decrease) in cash and cash equivalents
-116,091.273
116,187
-29,610
-15,473
Cash and cash equivalents, beginning of period
225,594
109,407
139,017
176,498
Cash and cash equivalents, end of period
205.134
225,594
109,407
139,017
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net loss$24,172.473K (172.30%↑ Y/Y)Purchase of property andequipment-$12.963K (-120.25%↓ Y/Y)Accounts payable andaccrued expenses$1,225.74K (240.57%↑ Y/Y)Other assets-$1.511K Net cash used inoperating activities$18,883.176K (169.70%↑ Y/Y)Net cash used ininvesting activities$12.963K (120.25%↑ Y/Y)Canceled cashflow$6,516.548K Net increase(decrease) in cash and cash...-$116,091.273K (-427.50%↓ Y/Y)Canceled cashflow$18,896.139K Proceeds from exercise ofstock options$1.015K (-98.87%↓ Y/Y)Share-based compensationexpense-$4,998.535K (-167.77%↓ Y/Y)Prepaid expenses andother current assets$1,494.343K (500.14%↑ Y/Y)Depreciation andamortization-$15.968K (-179.84%↓ Y/Y)Loss on disposal ofproperty and equipment$2.995K Deferred income taxes-$2.753K Foreign exchangetransaction loss$1.954K (102.92%↑ Y/Y)Net cash provided byfinancing activities-$134,987.412K (-2721.62%↓ Y/Y)Canceled cashflow$1.015K Proceeds from issuance ofclass a ordinary...-$123,751.629K Proceeds from issuance ofpre-funded warrants in...-$11,236.798K